Vanguard Portfolio Management
NGNE icon

Vanguard Portfolio Management’s Neurogene NGNE Stock Holding History

Vanguard Portfolio Management’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.01M Buy
95,601
+30,521
+47% +$840K ﹤0.01% 2601
2026
Q1 		$1.31M Buy
+65,080
New +$1.26M ﹤0.01% 2715

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Vanguard Portfolio Management's NGNE Position: Q2 2026 in Review

Vanguard Portfolio Management increased its Neurogene (NGNE) stake by 47% in Q2 2026, buying an estimated $840K and bringing the position to 95,601 shares worth $3.01M. The position accounts for ﹤0.01% of the portfolio, ranked #2601.

Vanguard Portfolio Management first reported a position in NGNE in Q1 2026 and has held it in 2 quarters since. 111 funds tracked by Wall St. Rank hold NGNE as of Q2 2026.

  • Vanguard Portfolio Management held 95,601 shares of Neurogene worth $3.01M as of Q2 2026.
  • Vanguard Portfolio Management bought 30,521 Neurogene shares in Q2 2026, an estimated $840K.
  • Neurogene made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #2601 holding.
  • Vanguard Portfolio Management first reported a position in Neurogene in Q1 2026 and has held it in 2 quarters since.
  • 111 funds tracked by Wall St. Rank held Neurogene as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.